PLAQUE REDUCTION WITH CONCURRENT REDUCTION/PREVENTION OF GINGIVITIS
This article was originally published in The Tan Sheet
Executive Summary
PLAQUE REDUCTION WITH CONCURRENT REDUCTION/PREVENTION OF GINGIVITIS are the most appropriate endpoints for demonstrating effectiveness of OTC plaque products, according to a draft "points to consider" document prepared by members of FDA's OTC Plaque Subcommittee and discussed at a Dec. 7 meeting.